New Delhi (SunstarTV Bureau): Bharat Biotech’s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase 2 and 3 clinical trial on those aged between two to 18 years, official sources said.
As per the official sources, the trial for the vaccine will take place in 525 subjects at different sites, including AIIMS, Patna, AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.
From May 1, 2021, the Indian Government had announced all adults above 18 years be eligible to receive the vaccination.
Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research ICMR), is being used in adults in India’s ongoing COVID-19 vaccination drive.
